Comparative Pharmacology
Head-to-head clinical analysis: ALINIA versus PENTACARINAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALINIA versus PENTACARINAT.
ALINIA vs PENTACARINAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitazoxanide is a thiazolide antiparasitic agent that inhibits the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction, which is essential for anaerobic energy metabolism in parasites.
Pentamidine is an antiprotozoal agent that interferes with the synthesis of nucleic acids and proteins, possibly through inhibition of dihydrofolate reductase and disruption of polyamine synthesis.
500 mg orally twice daily for 3 days, with food.
4 mg/kg IV once daily for 21 days for Pneumocystis jirovecii pneumonia (PCP) treatment; 300 mg (or 4 mg/kg) via nebulizer once monthly for PCP prophylaxis.
None Documented
None Documented
Terminal half-life of tizoxanide is approximately 1.5-2 hours in patients with normal renal function; clinical context: short half-life requires twice-daily dosing.
Terminal elimination half-life is 3-4 hours in patients with normal renal function, but can be prolonged to 18-24 hours in renal impairment.
Fecal (75-85% as tizoxanide), renal (5-10% as tizoxanide and conjugates), biliary (minor).
Renal: 10-20% unchanged; biliary/fecal: minimal; remainder metabolized.
Category C
Category C
Antiprotozoal Agent
Antiprotozoal Agent